Tyrosine hydroxylase (conversion of L-tyrosine to L-DOPA) and Aromatic L-amino acid decarboxylase (conversion of L-DOPA to dopamine) (TH (Tyrosine hydroxylase), AADC (Aromatic L-amino acid decarboxylase))

The phrase “Dopamine precursor conversion to dopamine in CNS” refers not to a single molecular target but to a biochemical pathway mediated primarily by the enzymes tyrosine hydroxylase and aromatic L-amino acid decarboxylase (AADC). Within the CNS, L-tyrosine is first converted to L-DOPA by tyrosine hydroxylase, and then L-DOPA is converted to dopamine by AADC. Drugs such as levodopa (L-DOPA) are used to increase brain dopamine by serving as this precursor, especially in diseases like Parkinson’s disease, where dopamine-producing neurons degenerate. Key therapeutic approaches inhibit peripheral metabolism of L-DOPA (e.g., carbidopa for AADC, entacapone for COMT) to increase CNS availability. Defining “Dopamine precursor conversion to dopamine” as a target is imprecise, as it encompasses a multi-enzyme pathway rather than a single molecular entity. The principal molecular targets are the enzymes responsible for the individual conversion steps, primarily tyrosine hydroxylase and aromatic L-amino acid decarboxylase[1][3][5][6][7][8]. The pathway is central to dopaminergic signaling and is heavily targeted in neurodegenerative disease therapy, but should be referenced in terms of its component enzymes for structured pharmacological applications.

Other names

L-DOPA biosynthesisdopamine biosynthesis pathwaydopamine synthesis enzymes

Enzyme substrate (levodopa as substrate for AADC) - Enzyme inhibition (carbidopa inhibits peripheral AADC, COMT inhibitors inhibit catechol-O-methyltransferase) - Dopamine replenishment (restoration of CNS dopamine)